A detailed history of Met Life Investment Management, LLC transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 26,668 shares of TBPH stock, worth $256,812. This represents 0.0% of its overall portfolio holdings.

Number of Shares
26,668
Previous 27,565 3.25%
Holding current value
$256,812
Previous $233,000 8.15%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$7.66 - $10.25 $6,871 - $9,194
-897 Reduced 3.25%
26,668 $214,000
Q2 2024

Aug 13, 2024

BUY
$8.29 - $9.92 $46,001 - $55,046
5,549 Added 25.2%
27,565 $233,000
Q1 2024

May 14, 2024

BUY
$8.22 - $11.59 $180,971 - $255,165
22,016 New
22,016 $197,000
Q4 2023

Feb 14, 2024

SELL
$8.58 - $11.4 $37,443 - $49,749
-4,364 Reduced 12.86%
29,578 $332,000
Q2 2023

Apr 29, 2024

BUY
$10.16 - $11.92 $344,850 - $404,588
33,942 New
33,942 $351,000
Q2 2023

Aug 10, 2023

BUY
$10.16 - $11.92 $344,850 - $404,588
33,942 New
33,942 $351,000
Q1 2023

May 09, 2024

BUY
$9.87 - $11.44 $335,007 - $388,296
33,942 New
33,942 $368 Million
Q4 2022

Jun 14, 2023

BUY
$9.65 - $11.34 $327,540 - $384,902
33,942 New
33,942 $381 Million
Q3 2022

Jun 14, 2023

BUY
$8.39 - $10.22 $284,773 - $346,887
33,942 New
33,942 $344 Million
Q2 2022

Jun 20, 2023

BUY
$8.41 - $10.34 $285,452 - $350,960
33,942 New
33,942 $308 Million
Q1 2022

May 10, 2024

BUY
$8.33 - $12.96 $282,736 - $439,888
33,942 New
33,942 $324,000
Q1 2022

Jun 20, 2023

BUY
$8.33 - $12.96 $282,736 - $439,888
33,942 New
33,942 $324 Million
Q4 2021

May 17, 2024

BUY
$7.42 - $11.05 $113,511 - $169,042
15,298 Added 233.41%
21,852 $241,000
Q4 2021

Jun 21, 2023

BUY
$7.42 - $11.05 $162,141 - $241,464
21,852 New
21,852 $241 Million
Q3 2021

May 17, 2024

SELL
$6.77 - $14.41 $81,036 - $172,487
-11,970 Reduced 64.62%
6,554 $48,000
Q3 2021

Jun 21, 2023

BUY
$6.77 - $14.41 $44,370 - $94,443
6,554 New
6,554 $48.5 Million
Q1 2021

May 17, 2024

SELL
$16.57 - $21.08 $57,862 - $73,611
-3,492 Reduced 15.86%
18,524 $378,000
Q1 2021

Jun 26, 2023

BUY
$16.57 - $21.08 $306,942 - $390,485
18,524 New
18,524 $378 Million
Q4 2020

Jun 22, 2023

BUY
$14.89 - $20.16 $316,472 - $428,480
21,254 New
21,254 $378 Million
Q3 2020

Jun 26, 2023

BUY
$14.79 - $22.49 $314,346 - $478,002
21,254 New
21,254 $314 Million
Q2 2020

May 24, 2024

SELL
$20.64 - $30.69 $15,727 - $23,385
-762 Reduced 3.46%
21,254 $446 Million
Q2 2020

Jun 26, 2023

BUY
$20.64 - $30.69 $438,682 - $652,285
21,254 New
21,254 $446 Million
Q1 2020

Jul 12, 2023

BUY
$17.84 - $31.21 $379,171 - $663,337
21,254 New
21,254 $491 Million
Q4 2019

Jul 12, 2023

BUY
$16.12 - $25.89 $317,402 - $509,774
19,690 New
19,690 $510 Million
Q3 2019

Jul 12, 2023

BUY
$16.51 - $23.78 $325,081 - $468,228
19,690 New
19,690 $384 Million
Q2 2019

Jul 12, 2023

BUY
$15.6 - $25.15 $307,164 - $495,203
19,690 New
19,690 $322 Million
Q1 2019

Jul 13, 2023

BUY
$22.57 - $28.15 $444,403 - $554,273
19,690 New
19,690 $446 Million
Q4 2018

Jul 13, 2023

BUY
$22.52 - $35.07 $443,418 - $690,528
19,690 New
19,690 $504 Million
Q3 2018

Jul 13, 2023

BUY
$22.83 - $32.67 $449,522 - $643,272
19,690 New
19,690 $643 Million

Others Institutions Holding TBPH

About Theravance Biopharma, Inc.


  • Ticker TBPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 66,782,400
  • Market Cap $643M
  • Description
  • Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...
More about TBPH
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.